Senti Bio Announces Additional $11.5 Million of Financing

Core Insights - Senti Biosciences, Inc. has secured an additional investment of approximately $10 million in gross proceeds from Celadon Partners, increasing the total raised in the PIPE financing round to$47.6 million [1][2][3] - The company received an additional $1.5 million from its$8 million grant from the California Institute for Regenerative Medicines (CIRM), bringing the total CIRM funding to $6.4 million [7] - The cash runway guidance has been extended into 2026, indicating improved financial stability for ongoing projects [1] Funding Details - The PIPE financing was led by Celadon Partners with participation from several institutional and accredited investors, including New Enterprise Associates (NEA) and Leaps by Bayer [3] - The net proceeds from the PIPE financing will be used to fund the development of the SENTI-202 program, manufacturing ramp-up, and other R&D activities [3][4] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [8] - The lead program, SENTI-202, targets hematologic cancers and has shown promising initial clinical data with complete remissions in 2 of 3 patients [8] - The company is advancing its Gene Circuits technology through partnerships with major firms like Roche/Spark Therapeutics and Bayer/BlueRock Therapeutics [8]